Your browser doesn't support javascript.
loading
PSMC5 insufficiency and P320R mutation impair proteasome function.
Yu, Zhong-Qiu; Carmichael, Jenny; Collins, Galen A; D'Agostino, Maria Daniela; Lessard, Mathieu; Firth, Helen V; Harijan, Pooja; Fry, Andrew E; Dean, John; Zhang, Jiuchun; Kini, Usha; Goldberg, Alfred L; Rubinsztein, David C.
Afiliação
  • Yu ZQ; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, United Kingdom.
  • Carmichael J; UK Dementia Research Institute, University of Cambridge, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, United Kingdom.
  • Collins GA; Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Box 134, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
  • D'Agostino MD; Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, United States.
  • Lessard M; Department of Biochemistry, Molecular Biology, Entomology, and Plant Pathology, Mississippi State University, 32 Creelman Street, Starkville MS 39762, United States.
  • Firth HV; Division of Medical Genetics, Department of Specialised Medicine, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada.
  • Harijan P; Care for Rare Canada Consortium, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, K1H 8L1, ON, Canada.
  • Fry AE; Division of Medical Genetics, Department of Specialised Medicine, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, Canada.
  • Dean J; Care for Rare Canada Consortium, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, K1H 8L1, ON, Canada.
  • Zhang J; Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Box 134, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
  • Kini U; Department of Paediatric Neurosciences, Box 107, Child development centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom.
  • Goldberg AL; All Wales Medical Genomics Service, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, United Kingdom.
  • Rubinsztein DC; Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom.
Hum Mol Genet ; 2024 May 22.
Article em En | MEDLINE | ID: mdl-38776958
ABSTRACT
The ubiquitin-proteasome system mediates the degradation of a wide variety of proteins. Proteasome dysfunction is associated with neurodegenerative diseases and neurodevelopmental disorders in humans. Here we identified mutations in PSMC5, an AAA ATPase subunit of the proteasome 19S regulatory particle, in individuals with neurodevelopmental disorders, which were initially considered as variants of unknown significance. We have now found heterozygotes with the following mutations P320R (6 individuals), R325W, Q160A, and one nonsense mutation at Q69. We focused on understanding the functional consequence of PSMC5 insufficiency and the P320R mutation in cells and found that both impair proteasome function and activate apoptosis. Interestingly, the P320R mutation impairs proteasome function by weakening the association between the 19S regulatory particle and the 20S core particle. Our study supports that proteasome dysfunction is the pathogenic cause of neurodevelopmental disorders in individuals carrying PSMC5 variants.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article